HOME › DRUGS › DACOMITINIB
ACTIVE SUBSTANCE / INN

DACOMITINIB

Brand name(s): VIZIMPRO, Vizimpro
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Carcinoma, Non-Small-Cell Lung
NDA211288
ACTIVE SUBSTANCE
Dacomitinib
REGULATORS
FDA · EMA
SPONSORS / MAH
Pfizer Europe MA EEIG, PFIZER
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
VIZIMPRONDA211288PFIZERPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
VizimproPfizer Europe MA EEIGAuthorised02/04/2019Carcinoma, Non-Small-Cell Lung

FULL INTELLIGENCE ON DACOMITINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →